Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caspofungin for invasive pulmonary aspergillosis in COPD
ChiCTR2400079780Phase 4Completed
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Jan 2024
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of caspofungin in Acute Invasive Aspergillosis and chronic obstructive pulmonary disease (COPD), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Clinical efficacy within 3 weeks. Started Jan 2024; status: completed.
02
Drugs
caspofungin
03
Conditions
Acute Invasive Aspergillosischronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ChiCTR2400079780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079780.